Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice

Background: Atezolizumab plus bevacizumab was approved for patients with hepatocellular carcinoma (HCC). Although clinical trials have revealed its efficacy, the outcomes in the real-world clinical practice are unclear. We retrospectively evaluated the efficacy and safety of atezolizumab plus bevaci...

Full description

Bibliographic Details
Main Authors: Hideki Iwamoto, Shigeo Shimose, Yu Noda, Tomotake Shirono, Takashi Niizeki, Masahito Nakano, Shusuke Okamura, Naoki Kamachi, Hiroyuki Suzuki, Miwa Sakai, Akira Kajiwara, Satoshi Itano, Masatoshi Tanaka, Taizo Yamaguchi, Ryoko Kuromatsu, Hironori Koga, Takuji Torimura, on behalf of The Kurume Liver Cancer Study Group of Japan
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
hepatocellular carcinoma
atezolizumab
bevacizumab
real-world data
Online Access:https://www.mdpi.com/2072-6694/13/11/2786

Internet

https://www.mdpi.com/2072-6694/13/11/2786

Similar Items